Sign In
Buy VANI
$1.28
-0.0200 (-1.54%)
At Close: Jun 03, 2026
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
07:45am, Thursday, 13'th Nov 2025
Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase
Vivani Medical, Inc. Announces Closing of Common Stock Offering
04:05pm, Tuesday, 28'th Oct 2025
ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
Insiders Are Buying These 3 Stocks Hand Over Fist
02:21pm, Tuesday, 28'th Oct 2025
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
07:15pm, Sunday, 26'th Oct 2025
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
08:30am, Friday, 03'rd Oct 2025
The Company expects to reestablish and announce a new record date as soon as possible The Company expects to reestablish and announce a new record date as soon as possible
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
09:15am, Wednesday, 24'th Sep 2025
ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
08:30am, Wednesday, 17'th Sep 2025
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision f
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
08:30am, Thursday, 04'th Sep 2025
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory cle
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
08:30am, Wednesday, 20'th Aug 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra lon
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
04:20pm, Wednesday, 13'th Aug 2025
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
09:40am, Monday, 02'nd Jun 2025
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
I Missed The Quantum Rally - I Won't Miss The Next One
05:47am, Tuesday, 20'th May 2025
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
04:30pm, Tuesday, 13'th May 2025
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-lin
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-a
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
08:30am, Tuesday, 15'th Apr 2025
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans Over half of all dogs in the Un
